Published Date: 02 Mar 2023
Many doctors have accused hospitals and large hospitals of opposing quality care and promoting violence. Others disagree.
Read Full NewsSubcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.
Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave immediate reaction to the EC approval of high-dose nusinersen and its implications for evolving SMA treatment strategies.
A recent phase 2b study reveals mesdopetam's potential in reducing dyskinesia severity in Parkinson disease, despite no significant ON time improvement.
1.
Renewing the call for a national Cancer Patient's Bill of Rights
2.
Charles III, King of Kings, is Cancerous.
3.
Combo of Approved Agents Active in High-Risk Large B-Cell Lymphoma
4.
Slowdown in progress found with cancer survival in England and Wales
5.
La interacción GBP3-STING en el glioblastoma coordina la respuesta deficiente al temozolomide.
1.
Epigenetics and Resistance: Mechanisms in Histone Methylation-Targeted Therapies
2.
Polyposis Syndrome: Causes, Symptoms, and Treatment Options
3.
Mitoxantrone–Napabucasin Co-Nanoformulation Activates cGAS-STING in HCC Therapy
4.
Beyond the Brain Fog: The Complex Neurological Challenges and Therapeutic Advances
5.
Lactic Acid-Linked lncRNAs in Wilms Tumor: Decoding the Tumor Microenvironment & Prognosis
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Further Discussion on A New Perspective
2.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
5.
Efficient Management of First line ALK-rearranged NSCLC
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation